Navigation Links
Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
Date:2/26/2008

CAMBRIDGE, Mass., Feb. 26 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the upcoming SIGnificant Investment Options in Healthcare Conference hosted by Susquehanna Financial Group on Wednesday, March 5, 2008 at 4:00 p.m. ET at the W Hotel in the Sea/Ocean Room in New York, NY.

The live and archived audio only webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at http://www.idenix.com. Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replays will be available on the Idenix website for two weeks following the conference. The company presentation will be available for download in PDF format in the "Investor Presentations" section of the Investor Center immediately following the presentation.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
2. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
5. Lotus Pharmaceuticals Raises $5 Million in Private Placement
6. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
7. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
8. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
9. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
10. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
11. NUCRYST Pharmaceuticals announces year-end results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services ... Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... will facilitate the development of a hub and spoke model for opioid treatment ...
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian Ayahuasca retreat, ... be awarded annually to and divided between two full-time university students enrolled in ... Amazonian plant medicine. To apply for the scholarship, students are asked to submit ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider ... partnered with WALLIX to expand its solution to help government contractors more ... a number of ways to address the authentication requirements within NIST SP800-171, but ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: